Exicure (XCUR) Stock Price

Exicure Price

NASDAQ·CLOSED
0.97
​
Market closed

Revenue at Exicure has contracted by 15.9% per year over the past 9 years to 500,000.00 USD. Exicure's net margin stands at -1,940.2%, up from -2,029.6% several years earlier. Analysts set a median price target of 2.04 USD, implying 111.0% above the current price. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus.

Exicure stock price

Access this data via the Eulerpool API

Exicure business model & stock analysis

Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). The company is headquartered in Chicago, Illinois and currently employs 43 full-time employees. The company went IPO on 2018-05-09. The firm is focused on developing therapeutics for immuno-oncology, genetic disorders and other indications based on its Spherical Nucleic Acid (SNA) technology. SNA is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Its pipeline includes AST-008, XCUR-FXN and XCUR17. AST-008 product is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. XCUR-FXN is a preclinical program for the treatment of Friedreich’s ataxia (FA). XCUR17 is being developed for inflammatory disorders, netherton syndrome and hair loss disorders. XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha (IL-17RA).

Frequently asked questions about Exicure

Analysts currently set an average price target of 2.04 USD for the Exicure stock (median: 2.04 USD), implying +111.0 % versus the latest price. The consensus is based on 6 analyst ratings.

6 analysts currently rate the Exicure stock: 0 recommend buying, 3 holding and 3 selling.

Converted at the current exchange rate, the Exicure share trades at 0.86 EUR (0.97 USD).

The Exicure share (XCUR) is listed on 1 stock exchanges, including: NASDAQ (XCUR).

The revenue cannot currently be calculated for Exicure.

The profit cannot currently be calculated for Exicure.

The P/E ratio cannot be calculated for Exicure at the moment.

The P/S cannot be calculated for Exicure currently.

The Eulerpool Quality Score for Exicure is 2/10.

The ISIN of Exicure is US30205M3097. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Exicure is A2PEAM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Exicure is XCUR. The ticker symbol is used to trade Exicure shares on the stock exchange.

Fair ValueTerminal
0.82 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
May 9, 2018
ISIN
US30205M3097
Cusip
30205M101
Sedol
BG0Q4Y1
Market capitalization
6.16 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
1.57
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-120.58 %
Last updated Oct 11, 2026, 7:21 AM

All fundamentals and in-depth analysis of Exicure

Our stock analysis for Exicure stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exicure. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.